Skip to main content
European Commission logo print header

Programme Category

Programma

Article available in the following languages:

EN

Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease: Phased expansion study

 

Objectives (restricted scope is expected for Phase 1)

  • to establish multiple key regional project sites (demonstration sites) across Europe to identify and test models of efficient earlier identification of mild AD dementia and prodromal AD patients, and awareness of AD risk;
  • to assess key tools, mechanisms and processes for community engagement and patient identification and resource utilization in various communities;
  • to compare and contrast various patient access models and how they contribute to improved detection, diagnosis, and clinical research in these communities;
  • based on findings, to establish archetypes of patient access models for implementation in similar communities, in synergy and collaboration with existing country specific government and non-government stakeholders;
  • to advocate and distribute access models for broader application and for replication.

Applicants are expected to address all the above objectives in th

The clinical paradigm for Alzheimer’s disease (AD) largely engages patients in the later clinical stages of disease, with the majority of patients and caregivers not seeking and/or receiving care until moderate or severe dementia has ensued. The current clinical paradigm does not support or emphasise the need for early detection, diagnosis or action when symptoms of AD first begin. To compound the issue, many physicians are reluctant to provide a diagnosis, because they perceive AD as an incurable disease without adequate treatment and supports. This lack of urgency not only currently compromises the quality of patient care, but also robs patients of access to available support resources and services. This lack of system preparedness for early action will also dramatically impact patient care once disease modifying agents are available.

The scientific community, many regulatory agencies, and advocacy groups are now aligned on the understanding that AD is a pathophysiologic neurodegenerative brain d

The intention of this action is to initially assess key metrics and access models for prioritization applicability. Methods and metrics should be analysed to measure efficiency and efficacy, and categorized into archetype models customized for various community types. Once successful archetype programs of paradigm shift are identified in successful models, they can be replicated in similar communities. This will be used to facilitate further development of independent efficient care models that engage more patients, engage them earlier in the course of disease, and provide access to a wider array of resources and aimed at improving access and enrolment in clinical research programs.